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Abstract
Infection by Shiga toxin-producing Escherichia coli causes hemorrhagic colitis, hemolytic uremic syndrome (HUS), acute
renal failure, and also central nervous system complications in around 30% of the children affected. Besides, neurological
deficits are one of the most unrepairable and untreatable outcomes of HUS. Study of the striatum is relevant because basal
ganglia are one of the brain areas most commonly affected in patients that have suffered from HUS and since the
deleterious effects of a sub-lethal dose of Shiga toxin have never been studied in the striatum, the purpose of this study was
to attempt to simulate an infection by Shiga toxin-producing E. coli in a murine model. To this end, intravenous
administration of a sub-lethal dose of Shiga toxin 2 (0.5 gg per mouse) was used and the correlation between neurological
manifestations and ultrastructural changes in striatal brain cells was studied in detail. Neurological manifestations included
significant motor behavior abnormalities in spontaneous motor activity, gait, pelvic elevation and hind limb activity eight
days after administration of the toxin. Transmission electron microscopy revealed that the toxin caused early perivascular
edema two days after administration, as well as significant damage in astrocytes four days after administration and
significant damage in neurons and oligodendrocytes eight days after administration. Interrupted synapses and mast cell
extravasation were also found eight days after administration of the toxin. We thus conclude that the chronological order of
events observed in the striatum could explain the neurological disorders found eight days after administration of the toxin.
Citation: Tironi-Farinati C, Geoghegan PA, Cangelosi A, Pinto A, Loidl CF, et al. (2013) A Translational Murine Model of Sub-Lethal Intoxication with Shiga Toxin 2
Reveals Novel Ultrastructural Findings in the Brain Striatum. PLoS ONE 8(1): e55812. doi:10.1371/journal.pone.0055812
Editor: Richard Jay Smeyne, St. Jude Children’s Research Hospital, United States of America
Received May 12, 2012; Accepted January 4, 2013; Published January 31, 2013
Copyright:  2013 Tironi-Farinati et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: These studies were supported by CONICET (National Research Council, Argentina) Grant PIP114-200801-00497 (http://www.conicet.gov.ar/web/
conicet/inicio) and Universidad de Buenos Aires (UBA) grant UBACYT 20020090200634 (http://www.uba.ar/secyt/contenido.php?id = 42&s = 50) to JG. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jogol@fmed.uba.ar
Introduction
Infection by Shiga toxin (Stx)-producing enterohemorrhagic
Escherichia coli (STEC) causes hemorrhagic colitis, hemolytic
uremic syndrome (HUS) [1], acute renal failure [2,3] and, less
commonly, central nervous system (CNS) impairment [4]. In
addition, it has been reported that the mortality rate from HUS
increases from 0–5% to 7–40% when the CNS is involved [5–8].
This issue became prominent in Germany in 2011 when the
consumption of sprouts containing Stx2 from the unusual
enteroaggregative E. coli O104:H4 resulted in 3816 cases of
gastroenteritis, 845 of which evolved to HUS and 54 to death. It
was noteworthy that, although STEC strains usually develop HUS
in children, in this case they affected adults, mainly women [9,10].
In addition, 48% of the 217 hospitalized patients intoxicated with
STEC in Germany developed severe neurological symptoms [11].
Argentina has the highest incidence of HUS in children under 5
years old (10.5 cases per 100,000) [12,13]. Mortality and severe
sequelae caused by STEC is still a persistent social and economic
problem for international public health.
In children, neurological symptoms appear about eight days
after the onset of hemorrhagic colitis. Symptoms include acute
seizures, coma, irritability, hemiparesis, aphasia and motor
alteration. Among these symptoms, seizures may potentially
predict mortality or long-term neurological sequelae. It has been
observed that neurological problems persist in 39% of surviving
children [5]. Although the deleterious effects of STEC on the CNS
are drastic, the pathogenic mechanisms whereby Stx2 causes CNS
impairment still remain to be elucidated.
Several animal models have been used to study the effects of Stx
on the CNS [14–18]. However, none has studied the deleterious
effects of intravenous administration of Stx2 on the striatum. The
neurological alterations described among models of Stx2 injection
in mice include hind limb paralysis [19], lethargy, shivering,
abnormal gait and spasm-like seizures [20]. Vascular and glial
changes have been observed at light microscope level [19,21,22].
Intraperitoneal administration of Stx2 causes both a glial
lamellipodia-like process that blocks spinal motor neuron synapses
[20] and endothelial damage in the cerebral cortex,
hippocampus and cerebellum [16–18,23,24]. In the rat model of
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intracerebroventricular (i.c.v.) Stx2 administration, ultrastructural
observation has revealed an apoptotic form of neuronal degener-
ation, demyelination, astrogliosis and pathological oligodendro-
cytes [25,26]. Rabbit models of Stx injection have shown
endothelial alterations like edema and hemorrhage [27–29], as
well as alterations in the myelin sheath, neuronal degeneration,
gliosis, vascular changes and hemorrhage in different brain areas
[30–32]. Pigs have been found to develop edema disease
characterized by CNS symptoms such as ataxia, and incoordina-
tion [33], convulsions, leg paddling and paralysis [34–37]. In
baboons, seizure episodes which progressed to coma and death
after i.v. administration of Stx2 have also been reported [38]. Stx1
causes ultrastructural lesions that are not observable with light
microscopy [39]. More details of animal models of Stx adminis-
tration can be found in a review written by Obata (2010) [40].
The study of the striatum is relevant because basal ganglia are
one of the most common brain areas affected in patients that have
suffered from HUS [41–43]. The striatum modulates the central
motor system [44,45] and is one of the most relevant brain regions
involved in neurological motor disorders in patients intoxicated
with STEC [46,47]. Magnetic resonance images (MRIs) have
revealed that basal ganglia are frequently involved in this
pathology [42,48]. A correlation between neurological deficits
and radiological images related to basal ganglia compromise in
comatose patients has been frequently reported [46,47]. However,
non-invasive methods such as MRI may not identify which cell
type is damaged or the extent of cell damage over a certain period
of the known toxin progression. In contrast, transmission electron
microscopy (TEM) is a powerful technique to detect the
ultrastructural state of these cells.
Thus, since the effects of sub-lethal i.v. doses of Stx2,
particularly in the striatum, have never been studied in an animal
model, in the present study we attempted to determine the type of
ultrastructural changes produced by Stx in the striatum and to
what extent these changes may resemble the human disease. We
also describe the correlation between the neurological alterations
observed and blood brain barrier disruption, mast cell extravasa-
tion, synapse interruption and striatal cell death.
Materials and Methods
Stx2 Purification
Stx2 was obtained as previously described [26]. Briefly, the
toxin was purified by affinity chromatography under native
conditions. Recombinant E. coli DH5a containing pStx2 were
cultured overnight. The supernatant obtained was precipitated in
60% SO4 (NH4)2 1 mM PMSF, and the pellet was dialyzed
overnight, resuspended in phosphate buffer solution (PBS) with a
cocktail of protease inhibitors, and incubated with Globotriose
Fractogel Resin (IsoSep AB, Tullinge, Sweden). The resin was
washed and the toxin eluted with MgCl2. Protein concentration
was determined in all the eluates. Protein content in all the
fractions was monitored by silver/Coomassie blue staining [49],
and the presence of Stx2 in the eluates was confirmed by Western
Blot analysis. Results showed a 7.7-kDa band corresponding to
Stx2B and a 32-kDa band corresponding to Stx2A. The same
batch of toxin was used for all the experiments.
The cytotoxic capacity of Stx2 was assessed in Vero cells by the
neutral red assay and the cytotoxic dose 50 (CD50) found was
about 1 pg/ml [50]. This effect was neutralized by means of
preincubation with an anti-subunit 2B monoclonal antibody (Sifin,
Berlin, Germany), and not neutralized when using an isotype
antibody instead [50]. Lipopolysaccharide (LPS) was removed
from the Stx2 solution by using Detoxi-gel (Pierce, Rockford,
USA). This Stx2 solution contained less than 0.03 endotoxin
units/ml.
Sub-lethal dose
The lethal effects of purified Stx2 were characterized in mice
(n = 4 per dose). Different amounts of Stx2 (5 to 0.44 gg per
animal) or vehicle were administered intravenously (i.v.) to mice
weighing about 20 grams. Survival time was established when
100% of the animals survived at least 8 days after administration
of 0.5 gg or less of Stx2. It was determined that with this dose
mice survived even for 10 days. This amount was thus considered
sub-lethal and selected for use in this study. The toxin was
administered twice (once a day for two consecutive days) with time
zero prior to initial administration of the toxin.
Animals
Male NIH mice (28–30 days old) were housed in an air-
conditioned and light-controlled (lights on between 7:00 am and
7:00 pm) animal facility. Animals were supplied by the animal
facility center of Administracio´n Nacional de Laboratorios e
Institutos de la Salud (ANLIS) Carlos G. Malbra´n, Buenos Aires,
Argentina. Mice were provided with food and water ad libitum and
neurological manifestations were monitored daily at the same time
throughout the experiment. The experimental protocols and
euthanasia procedures were reviewed and approved by the
Institutional Animal Care and Use Committee of the School of
Medicine of Universidad de Buenos Aires, Argentina (Resolution
No. 1099/10). All the procedures were performed in accordance
with the EEC guidelines for care and use of experimental animals
(EEC Council 86/609).
Behavioral motor tests
Mice were subjected to motor behavioral tests based on a
primary screening using a modified version of the SHIRPA-test
[51,52] 2, 4 and 8 days after i.v. administration of Stx2 or vehicle.
For the purpose of clarity, non-motor SHIRPA-screen behavioral
tests were not included. A total of three experiments were
performed using 12 mice per treatment. Animals were placed in
individual cages and the following motor behaviors were recorded
over a 5-minute period, without disturbing the animal: spontane-
ous motor activity (i.e. whether the animals had vigorous,
moderate, slow or no activity at all), gait (i.e. normal or abnormal),
pelvic elevation (i.e. whether animals were able to elevate their
body more than 3 mm from their horizontal axis, either normal
(not deviated from the axis) or barely touching the ground), and
hind limb activity (i.e. whether animals had normal or limited hind
limb movements). All the animals subjected to the treatments
described were given a score based on their motor capacity in the
motor tests. Normal behavior (vigorous activity, normal correct
posture, body not deviated from the axis and fluid hind limb
activity) was given a score of 0 and abnormal behaviors were given
a score of 1. The formula to calculate the SHIRPA score is:
SHIRPA score~P
abnormal motor behavior score per treatment time
N
 
+SD
where n (number of tests) = 4. Table 1 lists the motor behavioral
tests that showed significant differences between vehicle- and
Stx2-treated animals.
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Transmission Electronic Microscopy (TEM)
Mice were anesthetized with Chloral hydrate (350 mg/kg) and
perfused transcardially with 0.9% NaCl solution followed by 2.5%
glutaraldehyde in 0.1 M PBS [fixative per animal/weight (ml/g)]
for studies of Transmission Electron Microscopy (TEM). Brains
were removed from the skull and post-fixed in the same fixative
solution for 2 hours. Samples of dorsal striatum (3 mm2 thick)
were dissected and collected in 0.1 M phosphate buffer. The
samples were first assessed by light microscopy with blue toluidine
to select the areas for TEM. Ultrathin sections were cut from
selected areas [53] and then contrasted with 1% OsO4 and 1%
uranyl acetate, dehydrated and flat-embedded in Durcupan. The
sections were contrasted with lead citrate and then examined and
photographed on a Zeiss 109 electron microscope. Adobe
Photoshop software was used in the assembly of images (Adobe
Systems Inc., San Jose, CA, USA).
Statistical analysis
Twelve animals from each treatment group were subjected to
behavioral motor test studies. Four brain sections from each of
four animals (i.e. a total of 16 samples for each condition) were
used for TEM studies. The data are presented as mean 6 SEM.
Statistical significance was assessed by Student-t-test or one-way
analysis of variance (ANOVA) followed by Bonferroni post tests
(GraphPad Prism 4, GraphPad Software, Inc.). P values ,0.05
were considered significant.
Results
To test whether sub-lethal i.v. administration of Stx2 altered
motor behavioral function in mice, motor behavioral tests
consisting of four neurological assessments –spontaneous motor
activity, gait test, pelvic elevation and hind limb activity– were
conducted 2, 4 and 8 days after administration (Fig. 1). Results
evidenced motor functional deficiencies in which striatal damage
could be involved. Spontaneous motor activity of Stx2-treated
mice was reduced by 50% 4 days after administration and by
100% 8 days after administration. Reduced hind limb activity,
abnormal gait and increased pelvic elevation were observed in
75% of the Stx2-treated mice 8 days after administration. No
neurological differences were found between Stx2-treated mice
and the vehicle-injected group 2 days after administration.
Spontaneous motor activity, gait test, pelvic elevation and hind
limb activity were normal in vehicle-treated mice throughout the
eight experimental days. Behavioral changes in sensorial and
learning tasks were also monitored (data not shown). Consequent-
ly, a detailed ultrastructural study was performed.
Intravenous administration of Stx2 causes necrotic and
degenerative-like neurons
Conserved neurons of the striatum from the vehicle-treated
group showed pale nuclei and well-dispersed chromatin, intact
cytoplasmic and nuclear membranes, and intact mitochondria
dispersed in the cytoplasm (Fig. 2A). In contrast, striatal neurons
from the Stx2-treated group showed a progressive degenerative
condition (Fig. 2B–F). Two days after administration, the
cytoplasm started to become vacuolated and more contrasted
than in the vehicle-injected group (2B). Two and four days after
administration, nuclei in the samples from Stx2-treated mice
appeared electron dense, with increased heterochromatin con-
densation, and resembled the early changes seen in an apoptotic
state (2B, C). In these neurons, perinuclear clustering of altered
mitochondria occurred within darkened and condensed cyto-
plasm. In addition, altered nuclear and cytoplasmic membranes
were observed by ultrastructure two days after administration.
Loss and/or convergence of the two membranes was observed as
an earlier sign of neuronal damage. This feature could be seen
only by TEM. Indentations of the nuclear membrane were
frequently found 4 days after administration, compared with the
nuclei from the vehicle-treated group (Fig. 2C). The changes
observed over this period reflected a pathological condition as
nuclear indentation would be consistent with the beginning of an
apoptotic process. Eight days after administration, the predomi-
nant ultrastructural observation included neurons with cytoplas-
mic edema and shrunk nuclei (Fig. 2D, F), or neurons that were
already in a necrotic state (Fig. 2G). Complete alteration of the
endoplasmic reticulum, organelles and mitochondria were ob-
served in neurons with edema (Fig. 2B, C). A common feature
observed over the time periods analyzed was cell edema, which
Table 1. Behavioral motor tests.
Test Score =0 Score =1
Spontaneous motor activity Vigorous movement Slow movement
Gait Normal Abnormal
Pelvic Elevation Normal (elevation of 3 mm) Elevated (elevation of more than 3 mm)
Hind limb activity Normal Difficulty to move
doi:10.1371/journal.pone.0055812.t001
Figure 1. Behavioral motor test. Plotting of SHIRPA scores to
standardize results of four motor behavioral tests (spontaneous motor
activity, gait, pelvic elevation and hind limb activity). Arbitrary units
(a.u.) are the mean summation of the four independent tests for each
day and treatment (vehicle or Stx2). Normal behavior = 0; abnormal
behavior = 1. The vehicle-treated group (vehicle) shows no abnormal
behavior while the Stx2-treated group (Stx2) shows significant
abnormal behavior (*) on day 8 of toxin treatment (p,0.05).
doi:10.1371/journal.pone.0055812.g001
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Figure 2. Intravenous administration of Stx2 causes neuronal damage. Conserved striatal neuron after i.v. vehicle (saline) administration (A);
pale nucleus (N) and intact cytoplasm (c) and membranes (m); intact mitochondrion (arrow). After 2 days of treatment: vacuolated neuron with
contrasted cytoplasm (c) and nucleus (N) (B); heterochromatin condensation (h). After 4 days: more contrasted nucleus (N) with increased
heterochromatin (h) condensation and prominent indentation with loss of membranes (arrows) (C); vacuolated perinuclear mitochondrion (*) (C).
Neuron with edema and loss of regular nuclear shape on day 8 (D). Disorganized endoplasmic reticulum (R) in the cytoplasm with edema (E) at higher
magnification; loss of regular shape in the nucleus (F) of a neuron with edema (E); affected neuronal nucleus (N) with irregular shape and no apparent
surrounded cytoplasm; (Ol, oligodendrocyte) (G). These features are absent in striatal neurons of the vehicle-treated group (A). Quantification of the
percentage of damaged neurons with edema (H). Significant results are observed starting on day 4. Maximum number of neurons with edema in
Stx2-treated mice observed on day 8 (*) (H). Results are expressed as a percentage of the total number of neurons in an area of 3721 mm2. Data are
mean6SEM of 6–8 experiments (F and G). An asterisk denotes statistical significance, p,0.05. The scale bar in A applies to micrographs B–D and F–G.
doi:10.1371/journal.pone.0055812.g002
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increased over time (Fig. 2H) and was significantly maximum
(p,0.05) 8 days after Stx administration.
Intravenous administration of Stx2 causes edema in
astrocytes and mast cell infiltration
Normal astrocytes were observed in samples from vehicle-
treated mice, usually together with mitochondria, rough endo-
plasmic reticulum, Golgi apparatus, dispersed small vesicles and
glial filaments (Fig. 3A). In contrast, altered astrocytes were
observed in Stx2-treated mice after day 2 (Fig. 3B). About 20% of
the astrocytes observed exhibited edema (Fig. 3G). This was
accompanied by evident disorganized endoplasmic reticulum and
swollen mitochondria. However, the nuclear envelope was
conserved (Fig. 3C). On day 4, perivascular astrocytic edema
was also observed (Fig. 3D). Disorganized endomembranes and
swollen mitochondria were found in watery cytoplasm. In contrast,
nuclear integrity was not compromised (Fig. 3D). On day 8, loss of
nuclear electron dense elements that migrated to the cytosol
probably due to nuclear membrane rupture and swollen organelles
in watery cytoplasm was evidenced (Fig. 3E). Cytoplasmic edema
was the main feature observed throughout the experiment
(Figs. 3B–F). The percentage of astrocytes that displayed edema
increased to 60% on day 8 and was significantly higher than in
vehicle- or Stx2-treated mice after 2 or 4 days (Fig. 3G). Stx2
caused astrocyte damage in the brain striatum. In addition, mast
cell extravasation to the brain parenchyma was likely (Fig. 3F).
Mast cells are identified by ultrastructure because they have
numerous rounded non-laminated granules in comparison with
basophil cells, which have larger and laminated granules. Mast
cells may go through the Blood Brain Barrier (BBB) into the brain
parenchyma attracted by inflammatory mechanisms after the Stx2
insult. Here, a mast cell in contact with an astrocyte was observed
(Fig. 3C). Mast cells are early responders in the regulation of acute
BBB changes after cerebral ischemia and hemorrhage.
Intravenous administration of Stx2 alters BBB integrity
Endothelial vessels from striatal brain sections of vehicle-
injected mice kept their endothelial nucleus and cytoplasm
conserved (Fig. 4A). Organelles were well preserved and
mitochondria showed normal external and inner membranes.
Since the vascular basal membrane was found covered by intact
perivascular astrocytes, the BBB appeared intact. Intact perivas-
cular astrocytes contacted dendrites and axons covered with a
sheath of myelin. In contrast, a progressive intracytoplasmic
edema of perivascular astrocytes was observed after i.v. adminis-
tration of Stx2 starting on day 2 (Fig. 4B). An incipient edema was
evidenced in perivascular astrocytes on day 2, while a complete
watery edema was observed mainly on day 4 (Fig. 4C). Watery
edema with collapsed and shrunk endothelial cells was observed
on day 8 (Fig. 4D), although no apparent endothelial cell damage
was observed. Complete watery edema was maximum on day 8
(Fig. 4E). Accordingly, perivascular edema increased over time.
Intravenous administration of Stx2 causes interrupted
synapses
Interrupted synapses were observed in the striatum of Stx-2-
treated mice (Fig. 5). The number of interrupted synapses was
significantly higher in Stx2-treated animals than in vehicle-treated
ones. A projection of a reactive astrocyte interrupted the synaptic
Figure 3. Intravenous administration of Stx2 causes astrocytic edema and mast cell extravasation. Electron micrograph showing a
conserved astrocyte after i.v. vehicle administration (A); conserved mitochondria (*), endoplasmic reticulum (R) and gliofilaments (g). After 2 days:
astrocytes show significant cytoplasmic edema (B); disorganized endoplasmic reticulum (R) and swollen mitochondria (*) (C). After 4 days: evident
astrocytic edema along the perivasculature (D); disorganized endoplasmic reticulum (R) and swollen mitochondria (*) with disorganized inner
membranes. After 8 days: altered astrocyte showing watery cytoplasmic edema (e), disorganized rough endoplasmic reticulum (arrow) and
mitochondria with broken membranes (*) (E); a neighboring conserved oligodendrocyte can be observed. Extravasation of a mast cell (observable
granules, MC) in contact with an astrocyte (As) (F). Quantification of the percentage of damaged astrocytes showing edema (G). Significant results are
observed starting on day 4. The maximum number of astrocytes with edema in Stx2-treated mice is observed on day 8 (*). Results are expressed as a
percentage of the total number of astrocytes in an area of 3721 mm2. Data are mean 6SEM of 6–8 experiments (G). An asterisk denotes statistical
significance, p,0.05. The scale bar in A applies to A, B, and D–F electron micrographs.
doi:10.1371/journal.pone.0055812.g003
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transmission of neurons by standing between the pre- and the post-
synapse (Fig. 5B, C).
Intravenous administration of Stx2 causes ultrastructural
alterations in oligodendrocytes
Normal oligodendrocytes were identified by the presence of
round or oval nuclei containing heterochromatin in the periphery
of the nucleus and electron-dense dark cytoplasm in vehicle-
treated mice (Fig. 6A). Oligodendrocytes were also distinguished
for their cytoplasm ensheathed axons. Two days after i.v.
administration of Stx2, nuclei of affected oligodendrocytes started
to show an irregular shape, condensed chromatin and mild
retraction (Fig. 6B). However, the nuclear envelope was still intact.
In the perinucleus, an electron-dense cytoplasm with partial
vacuolization was evident. The ultrastructural features observed
suggest an early stage of apoptosis. In addition, disorganized
myelin sheaths were observed in apparently swollen axons. On day
4, a progressive deterioration of the oligodendrocytes was observed
(Fig. 6C). Nuclei became more irregular and shrunk. Further
retraction of the nucleus was observed and bulked chromatin was
evident. Nuclear fragments were also observed in the edematous
area. At this stage, perinuclear vacuolization extended to the
whole electron-dense cytoplasm and myelin appeared to be not
only disorganized but also thinner than on day 2. Axons covered
with myelin were irregular and electron dense contrasted. On day
8, oligodendrocytes showed contrasted nuclei and cytoplasm, and
boundaries between them were difficult to differentiate (Fig. 6D).
Loss of cell volume immersed in an edematous area was the main
feature at this stage. However, cytoplasmic projections that
resembled sheaths covering axons were still observable. Cell
damage, quantified on days 2, 4, and 8 according to the criteria
previously described (Fig. 6E), increased over time. Accordingly,
the number of cells displaying damage was significantly higher on
day 8 than on days 4 and 2.
Discussion
Sub-lethal administration of Stx2 caused motor behavioral
alterations that may be related to damage of striatal cells. To our
knowledge, this is the first report on the toxic effects of sub-lethal
doses of i.v. administration of Stx2 in mouse brain striatum.
The striatum is part of the basal ganglia, with a relevant role in
the control of voluntary movements and in the onset of disorders
[44,45]. This brain area is highly affected in patients intoxicated
with STEC [42,43,46–48]. Neurological complications have been
found in patients with HUS and basal ganglia injury after 6–7 days
of the onset of symptoms [47]. Although hind limb paralysis has
been described in animal models as a disturbance caused by Stx2,
Figure 4. Intravenous administration of Stx2 causes ultrastructural alterations at the blood brain barrier level. Electron micrograph
showing a conserved endothelial cell with conserved endothelial nucleus that constitutes a microvessel from a striatal brain slice after i.v.
administration of vehicle; microvessel surrounded by conserved synapses (arrows), dendrites (d) and myelinated axons (a) (A). Perivascular edema (e)
2 days after i.v. administration of Stx2 (B). After 4 days: more pronounced perivascular edema (e) (C). After 8 days: infarcted microvessel (arrow) with
perivascular edema (*) near a neuron (N) (D). No cytoplasmic membrane is observed in the neuron at this stage. Quantification of the percentage of
damaged microvessels by perivascular edema (E). Damage in microvessels begins to be significant on day 2 and is maximum on day 8 (*). Results are
expressed as a percentage of the total number of microvessels in an area of 3721 mm2. Data are mean 6SEM of 6–8 experiments (G). An asterisk
denotes statistical significance, p,0.05. The scale bar in A applies to micrographs B–D.
doi:10.1371/journal.pone.0055812.g004
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Figure 5. Intravenous administration of Stx2 causes synaptic modifications. Electron micrograph showing an apparently normal synapse
(s) and pre-synaptic vesicles (v) in the striatum (A). Electron micrograph showing an increased number of pre-synaptic vesicles together with an
incipient astrocytic process (*) in close proximity to a synaptic space (S) in the lower left corner (B). Electron micrograph showing full astrocytic
interposition in the synaptic space (*) while the pre-synaptic terminal is full of vesicles (C). Chart illustrating the process in the synaptic space (right
panel). Percentage of interrupted synapses in the striatum from Stx2-treated mice vs. vehicle-treated ones (D). An asterisk denotes statistical
significance, p,0.05. Results are expressed as a percentage of the total number of synapses in an area of 3721 mm2. The scale bar in A applies to all
micrographs.
doi:10.1371/journal.pone.0055812.g005
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this deficit has been related only to spinal cord motor neurons and
neither this nor other motor deficits have been associated with any
particular brain region [19,20]. The neurological deficits found in
this study on the basis of motor behavioral tests could be correlated
with the damage observed in the striatum and are consistent with
the mean time of onset of symptoms in patients that suffer from
neurological manifestation of HUS [5]. Other brain regions
associated with movement, including the motor cortex and the
pyramidal tract, may also be implicated in damage by Stx2.
Neurons from vehicle-treated striatum showed a normal
appearance compared with Stx2-treated ones [54,55]. In contrast,
ultrastructural alterations observed in the striatum after intrave-
nous Stx2 administration showed earlier signs of neuronal damage
and an apoptotic state [54,56,57]. Pathological nuclear indenta-
tions frequently found in neurons on day 4 have also been found in
Huntington’s chorea disease neurons in related animal models
[58–60] or following axonal injury [61]. Overall, the altered
Figure 6. Intravenous administration of Stx2 causes pathological alterations in oligodendrocytes. Conserved oligodendrocyte in striata
of brains treated with i.v. administration of vehicle; myelin formation in the cytosol (*) (A); electron-dense heterochromatin (h) mostly in the periphery
of a rounded nucleus; euchromatin (e) present as electron-lucent areas of the inner nucleus. An irregular nucleus is observed 2 days after Stx2
treatment (B): vacuolated cytoplasm (v); disorganized myelin (my); Edema (E) and swollen mitochondria in the extracellular space. A shrunk and
retracted nucleus (N) and perinuclear vacuolization (v) are observed on day 4 (C). Altered oligodendrocyte with a contrasted cytoplasm observed on
day 8 (D); nucleus (N) and cytoplasm are difficult to differentiate; extended edema (E) and lack of myelin (L); swollen and disorganized cristae in
mitochondria (m). The number of cells with edema increased with time (E). Results are expressed as a percentage of the total number of
oligodendrocytes in an area of 3721 mm2. Data are mean6SEM of 6–8 experiments. An asterisk denotes statistical significance, p,0.05. The scale bar
in A applies to B and C.
doi:10.1371/journal.pone.0055812.g006
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changes observed in these neurons reflect a pathological condition
of Stx2-treated mice.
In accordance with previous reports, normal astrocytes were
observed in vehicle treated-mice [62]. Astrocytes usually cover the
basement membrane of pial and vascular surfaces in the CNS, and
they surround neuronal bodies, axons and other neuronal
processes within the CNS. Under pathological conditions,
astrocytes may show increase in volume and large quantities of
filaments or watery swelling [62,63]. Failure of functionality in the
nuclear envelope could be the consequence of the osmotic changes
caused by the edema.
The microvasculature in the striatum from vehicle-treated mice
showed a conserved BBB ultrastructure [64,65] as compared with
that of Stx2-treated ones. Fujii et al. [14] found edematous
endothelial cells in the cortex of a moribund mouse 2 days after
injection of a lethal dose of Stx2 (4 gg per mouse). In contrast, we
have shown that a sub-lethal dose of 0.5 gg per mouse was
sufficient to cause a typical perivascular edema [64] and BBB
disruption by altering perivascular astrocytes. While we have
previously shown that intracerebral Stx2 causes vascular leakage
[26], in the present study we found that the toxin disrupts the BBB.
Interposition of astrocytic processes between the pre- and post-
synaptic terminals, namely astrocytic stripping, was observed in the
striatum. A similar physical blocking of lamellipodia-like processes
in the synapses of mouse motoneurons following Stx2 treatment has
been described [20]. Synapse interruption could be a neuroprotec-
tive mechanism whereby projections from astrocytes may physically
detach the synapse against excessive pre-synaptic release of
glutamate [66,67]. The altered synaptic terminals may be the
consequence of excessive glutamate release [20,68]. Therefore,
when an astrocytic interposition between a pre- and a post-synaptic
terminal occurs, post-synaptic densities may not be observed.
Mast cells were identified [69] and localized in the parenchymal
striatum, probably due to the pathological condition caused by the
toxin. These cells are usually located in the perivasculature [70]
and migrate into the brain parenchyma by an ischemic event
following brain swelling or alteration of BBB permeability [71].
Peripheral factors produced by Stx2 might contribute to mast cell
infiltration and astrocytic stripping, as these findings have not been
observed after local administration of Stx2 in rat striatum [26].
Nevertheless, structural differences between species might account
for this difference.
The oligodendrocytic phenotype may still be observed even in
the pathological condition [72]. In addition, oligodendrocytes and
microglial cells might be erroneously identified, unless ultrastruc-
tural differences become evident. When microglial cells become
activated by a noxious agent they display dilation of the
endoplasmic reticulum channels and a great number of electron
light vesicles in the cytoplasm. Also, a small number of activated
cells have electron-dense lysosomes, indicating phagocytic activity
[73]. As these features were not found in the injured cells, they
corresponded to oligodendrocytes. Apoptosis in oligodendrocytes
was observed at early stages [72], while necrosis was observed at
later stages [72,74]. Damage in oligondendrocytes might cause the
axonal transmission deficits observed in Stx2-treated mice, with
motor alterations including hind limb paralysis. Demyelinated
axons have been observed after the intracerebroventricular
administration of Stx2 [26].
Stx2 has been immunolocalized in the brain parenchyma
[20,26]. Although the receptor for Stx2 Gb3 is not localized in the
mouse brain endothelium [20], the toxin is nevertheless able to
bind to neurons. However, the mechanism whereby Stx2 enters
the brain parenchyma is still unknown. The BBB must keep a
healthy fluid environment to protect the brain parenchyma
[13,65] from harmful elements and to allow homeostatic influx
of various required substances and efflux of cell products to
maintain CNS homeostasis [71,75] and our results show that
vascular leakage as a result of Stx2 would alter this homeostasis.
The toxin may cross the brain parenchyma through vessels of
circumventricular organs that lack tight junctions, or by destroying
them in the non-fenestrated endothelia, or by first crossing the
blood-cerebrospinal fluid barrier to the ventricle space and then to
the brain parenchyma by crossing ependymal cells. Another
possibility is that the toxin crosses the BBB as a result of damage of
perivascular astrocytes that constitute a part of the barrier (Fig. 4).
The possible mechanisms behind the cell damage observed
include: i) cytotoxic action of Stx2 mediated by the Gb3 receptor
in neurons [20,50]; ii) contribution of peripheral or locally
produced pro-inflammatory cytokines and/or chemokines [76];
iii) deleterious collateral effect produced by kidney failure, which
could lead to electrolyte disorders and target the brain [76]; and iv)
energy depletion by lack of glucose and oxygen intake.
Regarding the second possible mechanism, it has been widely
reported that TNF-a contributes to the deleterious effects of Stx2
both in vitro [77] and in vivo [78]. Also, cytokines produced in the
brain have been reported [32] and their inflammatory effect could
partially explain the astroglial reactivity observed [25]. Under this
circumstance they can release more toxic products and target cells
in the vicinity, including neurons [79].
With regard to the fourth possible mechanism, BBB rupture
could prevent the incorporation of these substrates to neurons and
other cells. As a consequence, energy depletion would cause
membrane depolarization and the release of excitatory amino
acids into the extracellular space, leading to edema and apoptosis
in neurons and astrocytes [79].
In the present study, the ultrastructural lesions observed in the
striatal cells could have caused the motor behavioral alterations
found in Stx-treated animals. However, possible lesions produced
in other brain centers like the motor cortex and the pyramidal
tract cannot be discarded. The main input structure of the basal
ganglia is the striatum [80], which is specifically related to
voluntary limb movements [81]. The mechanistic entry of Stx2 to
the brain parenchyma and the subsequent events that lead to
neuronal and glial degenerative conditions are a current matter of
study. Other factors besides Stx2 may contribute to the described
pathology, and they should also be taken into account.
In summary, a sub-lethal i.v. dose of Stx2 caused BBB
disruption, astrocytic edema, neurodegeneration, oligodendrocyte
death, synapse interruption and mast cell extravasation, which
may explain the motor behavioral alterations and lethargy
observed in mice. This damage may also reflect some clinical
alterations observed in brain impairment by the toxin. Therefore,
this animal model appears to be useful to compare and understand
the basis of the neuropathogenic mechanisms underlying STEC
intoxication in patients.
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